Summit Therapeutics (SMMT) Postpones Planned Rights Offering

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. RKLB
7. VRNS
8. CAT
9. FMC
10. AA

Go back to Summit Therapeutics (SMMT) Postpones Planned Rights Offering

Summit Therapeutics Announces Postponement of Its Planned Rights Offering

February 9, 2022 8:00 AM EST

Cambridge, Massachusetts, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit or the Company) today announced the postponement of its previously announced rights offering to stockholders of record on February 4, 2022.

The Company had previously announced topline results for its Phase III Ri-CoDIFy study evaluating ridinilazole for the treatment of and Sustained Clinical Response (SCR) for patients suffering from C. difficile infection ("C. diff. infection" or "CDI"). The Company is continuing to evaluate the underlying data and perform additional analyses, including analyses specific to the microbiome, in order to... More